Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients

NCT03583528 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT03583528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03583528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients
Lead sponsor
British Columbia Cancer Agency
Phase
Observational
Overall status
Active, not recruiting
Start date
July 11, 2018
Completion date
September 30, 2028
Enrollment
800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid, ganglioneuroma, gastrinoma, glucagonoma, insulinoma, medullary carcinoma, medulloblastoma, meningioma, merkel cell carcinoma, neuroblastoma, neuroendocrine tumors, paraganglioma, pheochromocytoma, pituitary adenoma, small-cell lung cancer, vipoma